JP2023523083A5 - - Google Patents

Info

Publication number
JP2023523083A5
JP2023523083A5 JP2022565971A JP2022565971A JP2023523083A5 JP 2023523083 A5 JP2023523083 A5 JP 2023523083A5 JP 2022565971 A JP2022565971 A JP 2022565971A JP 2022565971 A JP2022565971 A JP 2022565971A JP 2023523083 A5 JP2023523083 A5 JP 2023523083A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
acid sequence
seq
bifunctional protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022565971A
Other languages
English (en)
Japanese (ja)
Other versions
JP7711095B2 (ja
JP2023523083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/089837 external-priority patent/WO2021218895A1/zh
Publication of JP2023523083A publication Critical patent/JP2023523083A/ja
Publication of JP2023523083A5 publication Critical patent/JP2023523083A5/ja
Priority to JP2025115631A priority Critical patent/JP2025148434A/ja
Application granted granted Critical
Publication of JP7711095B2 publication Critical patent/JP7711095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022565971A 2020-04-29 2021-04-26 PD-1とTGF-βに対する二機能性タンパク質 Active JP7711095B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025115631A JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010359751 2020-04-29
CN202010359751.8 2020-04-29
PCT/CN2021/089837 WO2021218895A1 (zh) 2020-04-29 2021-04-26 针对PD-1和TGF-β的双功能蛋白

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025115631A Division JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Publications (3)

Publication Number Publication Date
JP2023523083A JP2023523083A (ja) 2023-06-01
JP2023523083A5 true JP2023523083A5 (cg-RX-API-DMAC7.html) 2024-05-07
JP7711095B2 JP7711095B2 (ja) 2025-07-22

Family

ID=78331777

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022565971A Active JP7711095B2 (ja) 2020-04-29 2021-04-26 PD-1とTGF-βに対する二機能性タンパク質
JP2025115631A Pending JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025115631A Pending JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Country Status (9)

Country Link
US (1) US12668633B2 (cg-RX-API-DMAC7.html)
EP (1) EP4144763A4 (cg-RX-API-DMAC7.html)
JP (2) JP7711095B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230003178A (cg-RX-API-DMAC7.html)
AU (1) AU2021263650A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022020A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181579A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013620A (cg-RX-API-DMAC7.html)
WO (1) WO2021218895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN116925223A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pd-1单克隆抗体及其衍生物和用途
WO2023208191A1 (zh) * 2022-04-29 2023-11-02 广东菲鹏制药股份有限公司 一种重组抗体及其应用
WO2025251034A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Purification method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD120103A1 (cg-RX-API-DMAC7.html) 1975-07-07 1976-05-20
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
ES2820768T3 (es) * 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110050000B (zh) * 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
CN119735681A (zh) * 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
BR112020022145A2 (pt) 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
JP2021529557A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
CN112672753B (zh) 2018-07-09 2025-07-08 普瑞赛格恩公司 融合构建体及其使用方法
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
EP3990116A1 (en) * 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN110734498A (zh) 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
JP7495489B2 (ja) * 2019-10-21 2024-06-04 ナンチン リーズ バイオラブス カンパニー,リミティド PD-1およびTGFβを標的化する組換えタンパク質

Similar Documents

Publication Publication Date Title
Forsberg et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
Fan et al. Therapeutic application of anti-growth factor receptor antibodies
JP2019107018A5 (cg-RX-API-DMAC7.html)
JP2022505871A5 (cg-RX-API-DMAC7.html)
HRP20220133T1 (hr) Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe
KR100909290B1 (ko) 항암 항체
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
KR20190117493A (ko) 항 pd-1 항체 및 그의 용도
IL310938A (en) Anti-CCR8 antibodies and their uses
FI3515938T3 (fi) Monoklonaallisia vasta-aineita ohjelmoituun kuolemaan (PD-1)
JP2020506971A5 (cg-RX-API-DMAC7.html)
KR20210100654A (ko) Cd3 항체 및 그의 약제학적 용도
RU2015106147A (ru) Антитела против kit и их применения
CN112912109A (zh) 通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
RU2018105963A (ru) Антитело против глипикана-3 и его применение
JP2020530770A5 (cg-RX-API-DMAC7.html)
CN111995685B (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
IL272103B1 (en) Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
CN112969476A (zh) 多特异性蛋白分子
KR20200120648A (ko) 항pd-1/항her2 천연항체 구조 헤테로다이머계의 이중특이성 항체 및 그 제조방법
CN117157312A (zh) 蛋白酶活化的多肽
JP2008508858A5 (cg-RX-API-DMAC7.html)
JP2024528935A5 (cg-RX-API-DMAC7.html)
CN110092832A (zh) 抗ox40抗体及其用途
Sokolova et al. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency